Overview

Intravitreal Ranibizumab in Retinal Pigment Epithelial Detachments

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the efficacy of ranibizumab in patients with retinal pigment epithelial detachment secondary to age-related macular degeneration (AMD).
Phase:
Phase 4
Details
Lead Sponsor:
University Hospital Muenster
University Hospital, Bonn
Collaborator:
Novartis
Treatments:
Ranibizumab